Identification of lncRNA–miRNA–mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor

par Ting Wang, Chengliang Yang, Bing Li, Ying Xing, Jian Huang, Yangping Zhang, Shanshan Bu, Hong Ge
Publié 2021

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

par Yurong Wang, Ruipan Zheng, Peizhu Hu, Ziheng Zhang, Shujing Shen, Xingya Li
Publié 2021

Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

par Taichi Miyawaki, Hirotsugu Kenmotsu, Hiroaki Kodama, Naoya Nishioka, Eriko Miyawaki, Nobuaki Mamesaya, Haruki Kobayashi, Shota Omori, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Keita Mori, Hideyuki Harada, Masahiro Endo, Kazuhisa Takahashi, Toshiaki Takahashi
Publié 2021

ELF3 Is a Target That Promotes Therapeutic Efficiency in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Cells via Inhibiting PKCί

par Jeon-Soo Lee, Young Eun Choi, Sunshin Kim, Ji-Youn Han, Sung-Ho Goh
Publié 2021

Clinical Practice of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Drugs Combined with Gadolinium Oxide Nanoparticles in the Treatment of Non-Small Cell Lung...

par Xuan Zhou, Ting Jin, Likun Wang, Erlin Zhao, Xuyang Xiao
Publié 2021